Login to Your Account

Tumor metabolism and immunology specialist Calithera Biosciences Inc. on Tuesday revealed plans to raise up to $80 million in a yet-to-price initial public offering (IPO).
LONDON – Kalvista Pharmaceuticals Ltd. is celebrating a double success, advancing its lead product for treating diabetic macular edema (DME) into a phase I trial in patients and announcing the closing of a £5.5 million (US$9.2 million) series B funding.

Among the founders of cystic fibrosis (CF) player Proqr Therapeutics BV, which has filed to raise $75 million in an initial public offering (IPO), is a familiar name: Henri Termeer, former CEO of Genzyme Corp.

More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: